Target- |
MechanismImmunostimulants |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date27 Oct 2015 |
单中心随机盲法对照研究评估流感病毒裂解疫苗接种于3岁及以上年龄人群预防流感病毒感染的免疫原性和安全性
[Translation] A single-center, randomized, blinded, controlled study to evaluate the immunogenicity and safety of influenza virus split vaccine in preventing influenza virus infection in people aged 3 years and above
通过1剂免疫后21天的抗体阳转率证明流感病毒裂解疫苗在3岁及以上人群中的免疫原性非劣效于对照疫苗
[Translation] The immunogenicity of the influenza virus split vaccine in people aged 3 years and above was demonstrated to be non-inferior to the control vaccine as measured by antibody seroconversion rate 21 days after 1 dose of immunization
100 Clinical Results associated with Beijing Feituosi Trading Co., Ltd.
0 Patents (Medical) associated with Beijing Feituosi Trading Co., Ltd.
100 Deals associated with Beijing Feituosi Trading Co., Ltd.
100 Translational Medicine associated with Beijing Feituosi Trading Co., Ltd.